InspireMD, Inc. (NASDAQ: NSPR)

InspireMD, Inc. is a medical device company focused on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Its core offering is the CGuard™ carotid embolic prevention system, which combines a self‑expandable nitinol stent with a proprietary MicroNet™ mesh sleeve to provide embolic protection during carotid artery stenting procedures. The company also markets the next‑generation CGuard Prime stent platform and is advancing the SwitchGuard™ neuroprotection system for transcarotid revascularization.

InspireMD generates revenue primarily from the sale of its CGuard™ and CGuard Prime embolically protected stent systems to hospitals, ambulatory surgery centers, and specialty clinics. Revenue is derived through a network of international distributors that sell the products in Europe, Asia, Latin America, and the United States. The company also receives income from fees associated with clinical study supplies and limited sales of research‑use‑only devices, although the bulk of sales come from commercial stent placements.

InspireMD competes in the carotid artery stenting market against larger, well‑established medical device firms such as Abbott Laboratories, Medtronic plc, and Boston Scientific Corporation. Its competitive advantage lies in the proprietary MicroNet™ technology, which aims to reduce periprocedural stroke risk by capturing embolic debris. The recent U. S. FDA premarket approval for CGuard Prime and CE Mark certification under the EU’s Medical Device Regulation strengthen its regulatory standing and support its claim of offering a best‑in‑class embolic protection solution.

The company’s customer base includes interventional cardiologists, vascular surgeons, neurosurgeons, and the hospitals or catheterization laboratories where these physicians perform carotid artery procedures. InspireMD sells its products through distributors in more than thirty countries, including major markets in Germany, France, Italy, Spain, China, Japan, Brazil, and the United States. While specific customer names are not disclosed in the filing, the revenue base is broadly diversified across geographic regions and institutional accounts.